Navigation Links
OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
Date:10/6/2011

BERLIN, October 6, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.

The new Gallium-68-labeled radioactive contrast agent for positron emission tomography (PET) used by SOMscan has the potential to selectively detect and monitor neuroendocrine tumors. Following its potentialregistration, it could be, amongst other applications, used for this indication in conjunction with a new therapeutic drug.

SOMscan binds to four out of five specific receptor subtypes for the naturally-occurring hormone, somatostatin, on the cell surface of neuroendocrine tumors and uses high-resolution combined positron emission tomography and computed tomography (PET/CT) technique. This may allow detection of neuroendocrine tumors and metastases which previously escaped discovery in imaging diagnoses.  The only agent registered to date for the diagnosis of these tumors binds to only one of these receptor subtypes and uses the less sensitive gamma camera technique.

By leveraging high-resolution PET/CT imaging technique, the diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific - with a marked reduction of radiation exposure for the patient. The expectation is that tumors and metastases down to a size of approximately four millimeters can be detected in accurate anatomical correlation with SOMscan. Since both the SOMscan diagnostic and therapeutic agent bind to the same tumor receptors, this makes individual monitoring and management of the course of the disease possible - another step towards personalized medicine… [http://www.octreopharmsciences.com/images/pdf/20111005_ops_pressrelease.pdf].

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Campus Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  udo.blaseg@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
2. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
3. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
6. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
7. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
8. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
9. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
10. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
11. Sangamo BioSciences Announces Presentation at the Sixth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare ... Graduate Medical Education (ACGME) that it has received accreditation for its residency program ... three residency programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. ...
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is on ... security. Most importantly, employees are the single most important asset in creating value ... unhappy? , Just under half of American workers are emotionally checked out with ...
(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Coast Dental ... 16, 2016, at its new location in the Exchange Furniture Mall at 112 Vilseck ... for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet ...
Breaking Medicine News(10 mins):